Randomized trial predicts chemotherapy response in muscle-invasive bladder cancer, highlighting the need for multi-gene panels.
Key Points
This research aims to identify predictive biomarkers of response to platinum-based neoadjuvant chemotherapy in muscle-invasive bladder cancer patients.
Utilized high-throughput transcriptomics and immunohistochemistry on TUR-BT samples from NAC-naïve patients.
Conducted feature selection with Stable Iterative Variable Selection (SIVS) for biomarker identification.
Performed functional validation of a long non-coding RNA through in vitro overexpression in bladder cancer cells.
SIVS identified a gene panel successfully distinguishing chemoresistant from chemosensitive patients (AUROC > 0.8).
Three key protein-coding genes (PYGM, FOXQ1, LGALS7B) were validated immunohistochemically but showed limited predictive accuracy.
The long non-coding RNA DIO3OS had a slight, non-significant impact on cisplatin sensitivity in 5637 cells.